DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD

VANCOUVER, British Columbia and MENLO PARK, Calif., March 2, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, will participate in a Key Opinion Leader forum highlighting the Company's novel treatment for patients suffering from glioblastoma multiforme ("GBM"). The luncheon forum takes place on Thursday, March 9th at 12:00pm EST at the Lotte New York Palace Hotel in New York City.

The forum will feature a presentation by Dr. James Perry, MD who will discuss the current treatment landscape for GBM patients. In addition, DelMar's management team will provide an overview of VAL-083, the Company's "first-in-class," small-molecule chemotherapeutic addressing multiple forms of cancer, including MGMT-unmethylated and refractory GBM. 

DelMar recently announced the commencement of patient dosing in its Phase 2 trial for MGMT-unmethylated GBM at the University of Texas MD Anderson Cancer Center. VAL-083 has received an orphan drug designation in Europe for the treatment of malignant gliomas, and the U.S. FDA Office of Orphan Products has granted an orphan designation to VAL-083 for the treatment of glioma, medulloblastoma and ovarian cancer. 

Dr. James Perry, MD is the Chair of the Canadian Brain Tumour Consortium and the Head of Neurology at Sunnybrook Health Sciences Centre in Toronto. Dr. Perry is the Crolla Endowed Chair of Brain Tumour Research at Sunnybrook Odette Cancer Centre's Hurvitz Brain Sciences Program, Ontario Lead in CNS Oncology and a Professor of Medicine at University of Toronto. His neuro-oncology research interests include the design, conduct and analysis of clinical trials to test innovative therapies for primary brain tumors. Dr. Perry's clinical research related to the expression of MGMT and impact on outcomes of elderly glioblastoma patients was presented in a plenary session at ASCO2016 and he is involved in several ongoing clinical trials for patients with glioblastoma.

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com. 

A live and archived webcast of the event, with slides, will be available at http://lifesci.rampard.com/20170309/reg.jsp and on the Investors section of the Company's website at http://ir.delmarpharma.com. 

About Glioblastoma Multiforme (GBM)

GBM is the most common and the most lethal form of brain cancer. Approximately 15,000 new cases of GBM are expected to be diagnosed in the United States during 2017. GBM progresses quickly and patients deteriorate rapidly. Common symptoms include headaches, seizures, nausea, weakness, paralysis and personality or cognitive changes such as loss of speech or difficulty in thinking clearly. The majority of GBM patients do not survive for more than two years following diagnosis, and the median survival in newly diagnosed patients with best available treatments is less than 15 months.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. DelMar's VAL-083 is currently undergoing clinical trials in the U.S. as a potential new therapy for GBM. VAL-083 has been extensively studied by the U.S. National Cancer Institutes, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-participate-in-key-opinion-leader-luncheon-on-glioblastoma-multiforme-featuring-dr-james-perry-md-300416705.html

SOURCE DelMar Pharmaceuticals, Inc.